Ocena skuteczności bempedoic acid w połączeniu z lekami (ezetimibe, atorvastatin, rosuvastatin) u pacjentów z miażdżycą wieńcową bez zdarzeń sercowo‑naczyniowych

Confirmation of participation

After signing the consent form, the study team records basic information and schedules the first study visit.

Baseline measurements are performed, including blood tests, heart imaging, and documentation of medical history.

Start of triple therapy

The patient begins taking three oral medicines every day:

Atorvastatin 40 mg once daily, rosuvastatin 20 mg once daily, and a combined tablet containing bempedoic acid and ezetimibe 180.10 mg once daily.

The medicines are taken with or without food, according to the instructions provided.

First follow‑up visit (month 3)

At approximately three months after starting therapy, the patient returns for a visit.

Blood tests are repeated to check cholesterol levels and safety parameters.

Non‑invasive heart imaging may be performed to assess changes in plaque.

Second follow‑up visit (month 6)

At six months, another set of blood tests and imaging is done.

The study staff records any side effects or other health problems that occurred during the first six months.

Subsequent visits and end of treatment

Additional visits are scheduled roughly every three months until the planned end of the study (about 24 months from the start).

Each visit includes blood tests, imaging of the coronary arteries, and a review of any adverse events.

At the final visit, the primary outcome – change in plaque burden – is measured and compared with the baseline value.

Study completion

After the last assessments, the patient may stop the study medicines under supervision of the study physician.

Information about the reason for stopping the medication, if applicable, is recorded.